News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlycoVaxyn AG Phase I Clinical Study Shows Positive Data with Shigella Dysenteriae Vaccine Candidate



10/8/2010 9:39:22 AM

SCHLIEREN, Switzerland--(BUSINESS WIRE)--GlycoVaxyn AG, a leader in the development of innovative vaccines, announced today that the Phase I study of its Shigella dysenteriae bioconjugate vaccine has been completed and met the primary and secondary endpoints: demonstration of safety and immunogenicity.

Read at BioSpace.com


comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES